Pediatrics · LP-004
Chlorpheniramine maleate Syrup
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-004Pediatrics
- Generic identity
- Chlorpheniramine maleateSyrup
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-004
- Generic identity
- Chlorpheniramine maleate
- Presentation
- Syrup
- Catalogue strength
- 2 mg/5 mL
- Catalogue pack
- Bottle 60 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: chlorpheniramine maleate.
- Dosage form: syrup.
- Catalogue concentration: 2 mg/5 mL.
- Catalogue pack: bottle 60 mL.
- Catalogue category: Pediatrics; this is not evidence of a paediatric authorisation.
Layer 02 · Unresolved product-specific fields
- Approved age range, indication and dose for this exact product.
- Excipients, alcohol/sugar content, preservatives and whether shaking is required.
- Measuring-device specification and overdose-risk instructions.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 2 mg/5 mL | Syrup | — | Bottle 60 mL | Paediatric eligibility and formulation-specific safety/administration instructions require the exact controlled label. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Chlorpheniramine, also known as chlorphenamine, is a first-generation antihistamine used for allergy symptoms. It can cause sedation and has anticholinergic effects, which distinguish it from many newer allergy medicines. An oral syrup is a concentration-defined presentation, not evidence that the medicine is suitable for all pediatric ages. The information here concerns the ingredient and does not replace the approved local product information or an individualized clinical assessment.
Clinical context and therapeutic role
The reason for treatment should be established before selecting a sedating antihistamine. Allergic rhinitis, itching and hives have different diagnostic considerations, and persistent or severe symptoms may need additional assessment. It is not a treatment for anaphylactic shock and should not be used to sedate a child. A clinician or pharmacist should review age, other cough-and-cold preparations, sleep medicines and any conditions that increase vulnerability to anticholinergic effects.
Selected safety context
Drowsiness, dizziness, reduced coordination, dry mouth and blurred vision are important effects. Some children may become excited or agitated rather than sleepy. Alcohol, opioids and other sedating medicines can increase impairment. Glaucoma, difficulty passing urine and significant respiratory problems need particular review. Accidental overdose may be serious, especially in children. Seek urgent help for breathing difficulty, marked confusion, seizures, collapse, or an allergic reaction; use a proper medicine measuring device.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
This is a proposed liquid oral presentation with a stated concentration. The liquid vehicle, sweeteners, preservatives and whether the medicine requires shaking must be verified from the final label. A liquid format does not, by itself, establish that all age groups are eligible.
Use the product’s appropriate calibrated oral measuring device and verify concentration each time a new bottle is supplied. Keep the cap and label intact. Follow the actual instructions for storage and any period after opening; do not transfer advice from another brand or concentration.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Approved/controlled formula and composition.
Approved label/leaflet with age restrictions, indication and administration directions.
Container/closure and measuring-device specification.
Registration/market-status evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: About chlorphenamineArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 14 May 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
| MedlinePlus: ChlorpheniramineArchived source classification: US National Library of Medicine medicine reference | Source revision recorded: Last revised 15 March 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-004.
Professional enquiries
Request product-specific evidence for LP-004.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.